Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPharmacogenomics: personalizing pediatric heart transplantationPersonalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantationThe tacrolimus metabolism rate influences renal function after kidney transplantationHuman Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenA published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.Personalized Medicine in the Genomics Era: highlights from an international symposium on childhood heart disease.Stem cells in pediatric cardiology.Prevalence of renal dysfunction in tacrolimus-treated pediatric transplant recipients: a systematic review.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Pediatric perspective on pharmacogenomics.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Drug metabolism for the paediatrician.Choosing the right dose of tacrolimus.Personalised dosing of medicines for children.Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.A new donors' CYP3A5 and recipients' CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patientsCYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.Association of CYP3A variants with kidney transplant outcomes
P2860
Q26786582-14FC70F3-EFEB-46C0-A537-5C3BE3F17351Q28081200-BF2F992E-20DE-4537-9448-9AF1C88A183CQ28543706-5BEC9FFC-4E69-4360-95E8-901538BA26CDQ34395610-330AAFB0-5D4B-4E5F-9779-4B7BC3074B64Q35667919-756CCA79-2D4C-4459-A8B9-BF1D6360F326Q35782898-89018479-869C-4BCF-87BC-308A450665D8Q36322918-9D9AE52A-0605-468A-BA8C-E56CE6AB3061Q37161904-0B16F6C5-FDF9-49BE-A416-B68BC0D94F48Q37207789-81223C5F-9E3A-4161-93FD-4A4620B206C2Q37662992-046AD86B-51AA-437D-9D4E-D24489FEB154Q37993141-D5217EC6-6973-425C-92E1-0F2206EE6EA3Q38071902-141970AD-BBDF-479D-84B2-8D830EF091CCQ38085340-0394452C-7EAB-4276-A452-4E0DFF729A38Q38086777-620D5207-FB2C-4012-8182-3B1CA82091C2Q38162869-7E15E329-75F4-440D-BCCA-B881215EF1DAQ38163945-54BA8E10-E82A-4E22-94C4-36DBECE9A411Q38246000-524DCC32-7FA5-4463-AE9B-CF9171F4FB3BQ38270520-A8CD6CD1-4489-4533-8CF6-9BE433E2CEE7Q38749764-53638DE5-06FB-4490-B719-0C23C35D7AF9Q38806725-36D6A7F8-1A5D-40FE-923E-5131E6B9A244Q39675535-C4C43274-D2F8-463E-BAB2-087061F09169Q41107618-AAE0DE27-61E2-4EE4-9EE7-9541455C16CBQ42232484-21A299F4-922A-49A4-BB56-A8A97911C224Q42378424-CE5009E1-857B-4734-AC2C-D86FE010B829Q46136739-42C56B75-04F9-46BE-B2E1-D536C87C37F8Q46919747-8C6CCF01-69B5-4C49-B92A-2FCB4C8A522AQ47306662-F7FF4863-D908-437A-BD16-40F7D8983056Q55129457-E1AD5F23-B7C3-47CD-9422-0BEC275B3DDDQ57845197-CCFCD370-6698-4BBB-BF88-269A8C1A0DEF
P2860
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@ast
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@en
type
label
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@ast
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@en
prefLabel
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@ast
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@en
P2093
P2860
P1476
Age and CYP3A5 genotype affect ...... in pediatric heart recipients
@en
P2093
Gideon Koren
Ilse P van der Heiden
Irena Nulman
Offie P Soldin
Ron H van Schaik
Saskia N de Wildt
Seema Mital
Steven J Soldin
Violette Gijsen
P2860
P304
P356
10.1016/J.HEALUN.2011.08.001
P577
2011-09-17T00:00:00Z